Autopsy report · NCT02620384

Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.

“Limited resources available to met accrual goal.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 2 years 3 months before it stopped.
• 147 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Aultman Health Foundation

Sponsor type

University, hospital or other

Conditions

Acute Decompensated Heart Failure

Interventions

Experimental: Placebo; Experimental: Metolazone

Participants

147

Sites

1

Countries

United States

Trials that died the same way

• Amplification of Positivity for Alcohol Use Disorder Co-Occurring With Anxiety or Depression
  “Limited funding” (66% match in meaning)
• Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
  “Due to limited resources available to conduct study” (64% match in meaning)
• Local Radiotherapy Following Complete Resection of a Brain Metastasis
  “Too limited accrual” (62% match in meaning)
• Prediction of Expected Length of Hospital Stay Using Machine Learning
  “Insufficient resources.” (58% match in meaning)
• Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy
  “Slow accrual and funding limitations.” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.